Baidu
map

Nat Med:针灸有望用于治疗炎症

2014-02-27 佚名 生物360

针灸疗法(Acupuncture)起源于中国,在公元6世纪传到了朝鲜、日本等国。在现代作为替代疗法传播到世界各地。当针灸最初在西半球流行之时,它曾遭到到质疑。现在这样的质疑仍然存在。但随着时间的推移,通过细致的观察,科学家们已获得了实在的证据,证实这门医学艺术的古代中国实践者们确实是认识到了一些重要的东西。 日前,一项刊登在《自然-医学》Nature Medicine杂志上的最新研究证实了使

针灸疗法(Acupuncture)起源于中国,在公元6世纪传到了朝鲜、日本等国。在现代作为替代疗法传播到世界各地。当针灸最初在西半球流行之时,它曾遭到到质疑。现在这样的质疑仍然存在。但随着时间的推移,通过细致的观察,科学家们已获得了实在的证据,证实这门医学艺术的古代中国实践者们确实是认识到了一些重要的东西。

日前,一项刊登在《自然-医学》Nature Medicine杂志上的最新研究证实了使用针灸疗法与减轻败血症(sepsis)的一些身体过程之间的直接联系。败血症是一种由感染和炎症所引起,常常在发生在医院重症监护病房中的疾病,在美国每年导致大约 25 万人死亡。

论文资深作者、罗格斯大学新泽西医学院(Rutgers University New Jersey Medical School)的免疫学家 Luis Ulloa 表示:“败血症是医院中一个主要的死亡原因。但在许多情况下患者并非是因感染而死。他们是因为感染后形成的炎症性疾病而死亡。因此我们希望研究如何控制炎症性疾病。”

此前,研究人员已经知道,刺激身体的主要神经之一:迷走神经可以触动体内的一些过程减轻炎症,因此他们想看看采用一种针灸形式发送小强度电流通过迷走神经或其他神经,是否可能减轻败血症小鼠体内的炎症和器官损伤。 Ulloa 解释道:“增大电流可以放大针刺的效应,并且电疗已被美国食品药品监管局(FDA)批准用于治疗人类患者的疼痛。”

当研究人员向败血症小鼠施以电针之时,发现如预期的那样刺激了帮助限制炎症的细胞因子,一半的小鼠存活了至少一周。没有接受针灸的小鼠为零生存率。

Ulloa 和他的同事们随后开展进一步的详细调查,弄清楚了针灸疗法获得成功的原因。但他们生成了表面上非常令人失望的研究发现。他们发现当他们移除肾上腺(在体内生成激素的内分泌器官)时,电针不起作用。这一研究发现表面上指出了利用针灸治疗人类败血症的一个大的障碍,因为大多数人类败血症病例都存在肾上腺功能急剧下降。理论上,电针有可能仍然能帮助到肾上腺功能良好的少数患者,但对大量其他的患者则非如此。

研究人员展开了更深入的研究,发现了在具有正常功能肾上腺的情况下当施行电针时所发生的一些特异的解剖学变化。这些改变包括多巴胺水平升高。多巴胺是一种在免疫系统中发挥重要作用的物质。但他们发现单独添加多巴胺并没有抑制炎症。随后他们采用了一种叫做非诺多泮(fenoldopam)替代模拟多巴胺的一些最积极的影响,在没有针灸的情况下,他们成功地将败血症相关的死亡降低了 40%。

Ulloa 认为这些结果具有双重意义。一方面,这一研究超越以往显示了针灸价值的身体证据。他的结果显示,针灸不仅对于败血症,对于治疗其他的炎症性疾病,如类风湿关节炎、骨关节炎和克罗恩病都具有潜在利益。另一方面,通过确立一种药物可以减少小鼠败血症死亡,他为开发出潜在药物提供了一张创新的线路图。由于现在还没有任何药物获得FDA批准用于败血症治疗,这一线路图有可能具有至关重要的意义。

Ulloa 表示:“我并不知道在未来败血症最好的治疗方案将是电针或是一些模拟电针的药物。但底线是这项研究已经打开了通往两者的大门。”

原始出处:

Rafael Torres-Rosas, Ghassan Yehia, Geber Peña, Priya Mishra, Maria del Rocio, Thompson-Bonilla, Mario Adán Moreno-Eutimio, Lourdes Andrea Arriaga-Pizano, Armando Isibasi & Luis Ulloa. Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nature Medicine, 23 February 2014; doi:10.1038/nm.3479

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=79072, encodeId=45d9e9072a3, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79073, encodeId=89a8e90733d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:46:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79064, encodeId=225fe90646f, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79065, encodeId=7b63e9065ee, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79066, encodeId=5b0fe906618, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79067, encodeId=0129e9067c4, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79068, encodeId=ada0e90682c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79069, encodeId=8663e90693a, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79070, encodeId=6a8ae907083, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79071, encodeId=8c11e9071bf, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 08:45:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

相关资讯

Cancer:针灸只具备心理安慰作用?

一项最新研究称,传统的中医针灸疗法事实上只具备一种心理安慰作用。日前,刊登在《癌症》(Canner)杂志上的一项最新研究称,虽然针灸(Acupuncture)已经被使用了数千年,但是这并不意味着它就有效,它所带来的任何治疗效果或许就是一种心理安慰。来自美国马里兰大学等机构的研究人员追踪调查了 47 位使用芳香化酶抑制剂的妇女,这种治疗乳腺癌的药物会导致更年期一样的副作用(比如热潮红和盗汗),而且会

AIM:针灸确有止痛功效

    针灸作为中国传统医学,其效果能否经受西方近代科学的检验一直是广受关注的问题。英国南安普敦大学等机构的研究人员完成的一项最新研究认为,针灸的止痛功效是确实存在的。     南安普敦大学教授乔治·莱威思参加的一个国际科研小组在新一期《内科学文献》(Arch Intern Med. )杂志上报告说,对过去29项针灸研究中近2万人资料的调查显示,

针灸可改善冠心病患者心率变异性

    洛杉矶市西奈山医学院女性心脏中心的Puja K. Mehta医生报告,一项设有假针灸对照组的单盲研究显示,针灸治疗可通过调节交感迷走神经完成自主性重构,表现为心率变异性(HRV)增加。这项初步研究中有临床意义的HRV改善,为未来对冠心病患者开展传统针灸治疗的大型临床试验奠定了基础。    在已有明确冠心病的美国患者中,每年有大约1

spine:针灸可缓解慢性腰痛患者疼痛

尽管目前中医饱受诟病,但中医针灸在治疗多种疾病确实发挥了一定的作用。在骨科中,针灸通常被应用于疼痛治疗领域。近日,spine杂志上发表了来自爱尔兰学者的关于针灸的META分析文章,文章结论认为针灸可缓解慢性腰痛患者的自我疼痛感觉,改善功能。 研究者通过检索网络主流数据库,并按严格的纳入,排除标准进行meta分析的文献选择,最后共筛选出25例研究纳入分析。 Met

DDW 2013:自行无针针灸治疗控制糖尿病胃轻瘫患者消化不良有效

  在5月18日至5月21日召开的美国消化疾病周上,来自美国田纳西技术大学医学部的研究人员Sarosiek发表题为《自行无针针灸治疗控制糖尿病胃轻瘫患者的消化不良与胃食管反流症状》的论文。针灸是通过刺激皮肤内的针灸穴位治疗患者的一种替代医学方法。临床适应证包括控制疼痛及消化不良症状。对照研究的缺乏是文献中结果不一致的主要原因。检验采用定制的无线微刺激器进行无针经皮电神经刺激(TEA)的新方法,评价

AIM:针灸或有助缓解慢阻肺症状

近日,日本一个研究团队在美国《内科学文献》Archives of Internal Medicine网站上发表论文说,他们完成的小型临床试验显示,针灸可能有助缓解慢性阻塞性肺病(慢阻肺)患者的呼吸困难症状。 研究人员将68名有呼吸困难症状的慢阻肺患者随机分为两组,其中一组患者每周接受针灸治疗,针灸部位为手臂、后背、胸部以及腿部可能与哮喘及其他肺部疾病有关的穴位,对照组则接受虚拟针灸治疗,

Baidu
map
Baidu
map
Baidu
map